Azitra Inc (AZTR)
XASE:AZTR
Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.30
-$0.02(-5.17%)
At close: 4:00 PM EST
$0.30
-$0.02(-5.17%)
Day’s Range― - ―
52-Week Range$0.10 - $2.40
Previous CloseN/A
Volume201.32K
Average Volume (3M)169.78K
Market Cap
$3.43M
Enterprise Value-$9.71B
Total Cash (Recent Filing)$10.05M
Total Debt (Recent Filing)$343.33K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-2.83K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.51K
Enterprise Value/Ebitda883.65
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Strain Library + AI/MLA ~1,500-strain library combined with AI/ML gives durable discovery scale and differentiation. This platform can repeatedly generate candidate leads, accelerate target-to-candidate timelines, and support both therapeutic and cosmeceutical programs, underpinning long-term pipeline expansion and partnership value.
PIPE Financing Provides Staged CapitalThe March PIPE injects near-term non-dilutive-ish capital and optional follow-on cash if warrants are exercised, extending runway to advance cosmetic protein/peptide programs and R&D. This funding materially reduces immediate financing pressure and increases probability of reaching commercialization milestones.
Improved Headline CapitalizationRecent balance-sheet improvement and modest debt relative to equity reduce insolvency risk versus prior years. Manageable leverage gives the company structural flexibility to fund operations, pursue partnerships, and execute development plans without immediate refinancing urgency, supporting stability over months.
Bears Say
Revenue Fell To $0 In 2025/TTMA drop to zero reported revenue eliminates evidence of recurring commercial traction and undermines the business model. Without sustained sales, the company must rely on financings to fund development, making long-term commercialization and margin sustainability highly uncertain over the next several quarters.
Severe Cash Burn And Negative Cash FlowOperating and free cash flow are consistently negative and worsened in the trailing period, meaning accounting losses translate into real cash outflows. Persistent cash burn increases dilution risk, limits ability to fund trials or launches, and raises the probability of repeated financings that can disrupt strategy.
NYSE Noncompliance & Governance OverhangExchange noncompliance, a going-concern warning, and adjourned shareholder meetings signal structural governance and listing risk. Potential delisting would raise capital costs, shrink investor interest, and complicate partnerships and commercialization, materially increasing execution risk in the medium term.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $2.40 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $3.43M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Aug 17, 2026 which is in 63 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.24.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Undervalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.12.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 16,192,438 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(233.33% Upside)
Technical Analysis
Ownership Overview
4.47%
Insiders
0.47% Mutual Funds
0.14% Other Institutional Investors
94.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---